Veradermics, Inc Sample Contracts
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 1st, 2026 • Veradermics, Inc • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of April 29, 2026, between Veradermics, Incorporated, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • January 28th, 2026 • Veradermics, Inc • Pharmaceutical preparations • Connecticut
AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) made as of January 26, 2026, by and between Veradermics, Incorporated, a Delaware corporation (the “Company”), and Reid Waldman (the “Executive”), to be effective as of the effectiveness of the Company’s registration statement on Form S-1 with respect to the initial public offering of its common stock (the “Effective Date”). In the event that the Company’s registration statement on Form S-1 does not become effective, this Agreement shall be null and void and of no force or effect.
COLLABORATION AGREEMENTCollaboration Agreement • January 9th, 2026 • Veradermics, Inc • Pharmaceutical preparations
This Collaboration Agreement (as it may be amended from time to time in accordance herewith, the “Agreement”) is entered into effective as of September 21, 2020 by and between Therapeutics, Inc., a Delaware corporation (“Therapeutics”), located at 9025 Balboa Avenue, Suite 100, San Diego, CA, 92123 and VeraDermics, Incorporated, a Texas corporation (“VeraDermics”), located at 1031 West Elsmere Place, San Antonio, TX 78201. Therapeutics and VeraDermics are also referred collectively as “Parties” or singly as a “Party.”
MASTER SERVICE AGREEMENTMaster Service Agreement • January 9th, 2026 • Veradermics, Inc • Pharmaceutical preparations • California
This Master Service Agreement, (“Master Agreement”) effective September 21, 2020 (“Effective Date”), is made by and between Therapeutics, Inc., a Delaware corporation with corporate offices located at 9025 Balboa Avenue, Suite 100, San Diego, CA 92123 (hereinafter “THERAPEUTICS” or “TI”) and VeraDermics, Incorporated, a Texas corporation with corporate offices located at 1031 W. Elsmere Place, San Antonio, TX 78201 (hereinafter “VERADERMICS”), singly referred to as a “Party” or collectively as the “Parties”.
VERADERMICS, INCORPORATED INCENTIVE STOCK OPTION AGREEMENTIncentive Stock Option Agreement • January 28th, 2026 • Veradermics, Inc • Pharmaceutical preparations
This agreement (this “Agreement”) evidences a stock option granted by Veradermics, Incorporated (the “Company”) to the individual named above (the “Participant”), pursuant to and subject to the terms of the Veradermics, Incorporated 2026 Equity Incentive Plan (as from time to time amended and in effect, the “Plan”). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.
•] Shares of Common Stock (or Pre-Funded Warrants in lieu thereof) Veradermics, Incorporated UNDERWRITING AGREEMENTUnderwriting Agreement • April 27th, 2026 • Veradermics, Inc • Pharmaceutical preparations • New York
Price per Share to the public: [•] Price per Pre-Funded Warrant to the public: [•] Number of Shares (or Pre-Funded Warrants in lieu thereof) being sold by the Company: [•] Number of Shares potentially issuable pursuant to the option to purchase additional Shares: [•]
VERADERMICS, INCORPORATED THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • January 28th, 2026 • Veradermics, Inc • Pharmaceutical preparations • Delaware
THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of October 14, 2025, by and among VERADERMICS, INCORPORATED, a Delaware corporation (the “Company”), and the individuals and entities listed on Exhibit A (each an “Investor” and, collectively, the “Investors”), and each of those stockholders of the Company listed on Exhibit B hereto (each of whom is referred to herein as a “Key Holder” and collectively, the “Key Holders”).
INDEMNIFICATION AGREEMENTIndemnification Agreement • January 28th, 2026 • Veradermics, Inc • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into as of [•], 2026 between Veradermics, Incorporated, a Delaware corporation (the “Company”), and [•] (“Indemnitee”).
●] Shares Veradermics, Incorporated UNDERWRITING AGREEMENTUnderwriting Agreement • January 28th, 2026 • Veradermics, Inc • Pharmaceutical preparations • New York
VERADERMICS, INCORPORATED NON-STATUTORY STOCK OPTION AGREEMENTNon-Statutory Stock Option Agreement • January 28th, 2026 • Veradermics, Inc • Pharmaceutical preparations
This agreement (this “Agreement”) evidences a stock option granted by Veradermics, Incorporated (the “Company”) to the individual named above (the “Participant”), pursuant to and subject to the terms of the Veradermics, Incorporated 2026 Equity Incentive Plan (as from time to time amended and in effect, the “Plan”). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.